Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Actelion

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Actelion's 2013 sales performance.

J&J’s MS drug ponesimod receives approval in the US

J&J’s MS drug ponesimod receives approval in the US The pharma giant acquired the S1P1 receptor modulator as part its $30bn takeover of Actelion, with the FDA approval based in part on the head-to-head phase 3 OPTIMUM study

Sourcing R&D innovation: why pharma companies need to evolve their business models

Sourcing R&D innovation: why pharma companies need to evolve their business models including Shire/Takeda, Actelion/J&J, Sanofi Genzyme, Alexion, Amicus, BioMarin, Sarepta and Vertex.

Switzerland: a life sciences hub

Switzerland: a life sciences hub The Swiss flagship pharma and biotech companies such as Roche, Novartis, Actelion and ACImmune tend to garner a lot of attention, but in their small home country there is a rich ... Swiss companies like Idorsia, created by the founders of Actelion

Azafaros expands executive team with three senior hires

Azafaros expands executive team with three senior hires Prior to this, he held global clinical development and medical affairs leadership roles at Actelion Pharmaceuticals.

J&J aims for US approval of MS drug ponesimod

J&J aims for US approval of MS drug ponesimod J&J acquired the S1P receptor modulator as part its $30bn takeover of Actelion, with the FDA application based on the head-to-head phase 3 OPTIMUM study comparing ponesimod to

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...